Mutations in presenilin 1 and presenilin 2 (PS1 and PS2, respectively) genes cause the large majority of familial forms of early-onset Alzheimer's disease. The physical interaction between presenilins and APP has been recently described using coimmunoprecipitation. With a similar technique, we confirmed this interaction and have mapped the interaction domains on both PS2 and APP. Using several carboxy-terminal truncated forms of PS2, we demonstrated that the hydrophilic amino terminus of PS2 (residues 1 to 87, PS2NT) was sufficient for interaction with APP. Interestingly, only a construct with a leader peptide for secretion (SecPS2NT) and not its cytosolic counterpart was shown to interact with APP. For APP, we could demonstrate interaction of PS2 with the last 100 but not the last 45 amino acids of APP, including therefore the A␤ region. Accordingly, SecPS2NT is capable of binding to A␤-immunoreactive species in conditioned medium. In addition, a second region in the extracellular domain of APP also interacted with PS2. Comparable results with PS1 indicate that the two presenilins share similar determinants of binding to APP. Confirming these results, SecPS2NT is able to inhibit PS1/APP interaction. Such a competition makes it unlikely that the PS/APP interaction results from nonspecific aggregation of PS in transfected cells. The physical interaction of presenilins with a region encompassing the A␤ sequence of APP could be causally related to the misprocessing of APP and the production of A␤1-42.
INTRODUCTION
The large majority of early-onset familial Alzheimer's disease (AD) 2 cases are linked to mutations on the two homologous presenilin genes, PS1 and PS2 (Levy-Lahad et al., 1995; Rogaev et al., 1995; Sherrington et al., 1995) . Presenilins are transmembrane proteins with at least six transmembrane regions (Doan et al., 1996; Lehmann et al., 1997; Li & Greenwald, 1996) . All pathological mutations reported so far (over 40) are missense mutations except for one leading to deletion of one exon, which suggests a pathological gain of function (Hardy, 1997). However, the physiological function of PS is still largely uncharacterized. Both presenilins are expressed ubiquitously. In the central nervous system, presenilins are expressed essentially in neurons, with a large distribution throughout the brain (Elder et al., 1996 , Kovacs et al., 1996 Moussaoui et al., 1996) . At the subcellular level, presenilins are localized in the endoplasmic reticulum (Cook et al., 1996; Kovacs et al., 1996; Moussaoui et al., 1996) , a cellular compartment where a large fraction of APP is
